Latest Oligodendrocyte Stories
Wayne State University School of Medicine researchers, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis (MS) may play a role in the disease's progression.
Some neurological conditions such as multiple sclerosis and cerebral palsy are associated with the inability to repair the chronic destruction of myelin sheaths that surround the core of a nerve fiber and function to speed transmission of nerve impulses.
Around 100 billion neurons in the human brain enable us to think, feel and act.
Researchers at the Perinatology Research Branch of the National Institutes of Health, located at the Wayne State University School of Medicine and the Detroit Medical Center, have demonstrated that a nanotechnology-based drug treatment in newborn rabbits with cerebral palsy (CP) enabled dramatic improvement of movement disorders and the inflammatory process of the brain that causes many cases of CP.
Millions of adults suffer from the incurable disease multiple sclerosis (MS). It is relatively certain that MS is an autoimmune disease in which the body's own defense cells attack the myelin in the brain and spinal cord.
Scientists have improved upon their own previous world-best efforts to pluck out just the right stem cells to address the brain problem at the core of multiple sclerosis and a large number of rare, fatal children’s diseases.
Through the identification of a gene's impact on a signaling pathway, scientists at Children's National Medical Center continue to make progress in understanding the mechanics of a key brain developmental process: growth and repair of white matter, known as myelination.
Scientists at Case Western Reserve University School of Medicine found a way to rapidly produce pure populations of cells that grow into the protective myelin coating on nerves in mice.
Narcolepsy is a rare disorder characterized by an excessive urge to sleep at inappropriate times and places.
ATLANTA, Aug. 16, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.